Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
about
Domperidone-induced dystonia: a rare and troublesome complicationMortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study.Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study.A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trialThe benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial.Pharmacogenetics of antipsychotic-induced side effectsNeuroleptic medication and sexuality: the forgotten aspect of education and care.Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.Emerging drug therapies in Huntington's disease.Sex-specific differences in side effects of psychotropic drugs: genes or gender?Special issues in managing long-term mental illness in women.Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.Adolescents on neuroleptic medication: is this population at risk for tardive dyskinesia?Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature.How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review.Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain.Neuroleptic treatment of agitation and psychosis in dementia.Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist.Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia.Sex differences in use of psychotropic drugs and drug-induced side effects in schizophrenia patients: findings of the Research on Asia Psychotropic Prescription (REAP) studies.Pharmacological management of akathisia in combination with psychological interventions by a mental health nurse consultant.Suicide risk and antipsychotic side effects in schizophrenia: nested case-control study.Effect of haloperidol on measures of craving and impaired control in alcoholic subjects.Modification of haloperidol-induced pattern of c-fos expression by serotonin agonists.Placebo response in refractory tardive akathisia.Transdermal drug delivery system of haloperidol to overcome self-induced extrapyramidal syndrome.Therapy development in Huntington disease: From current strategies to emerging opportunities.
P2860
Q33833735-3118008F-13B3-4495-AE8F-386817925BB7Q34039590-2F74A188-CC8C-418A-B47D-6F029B5EB779Q34151743-0FB77879-08CB-4E67-809D-B695D158D0C1Q34183522-7E75AE20-E791-4973-A3A4-60DC6E7346F2Q34480263-9167AA00-66F3-4185-AAB3-696F0ACFD417Q35154166-F5ACEB26-F138-40E3-B092-16635A76E6C2Q35237129-FBE5E173-B8D5-43F0-8943-D561DEA2ABFAQ36191164-F1C78F0B-051C-4CCB-837A-D9C51284DC52Q36346334-56313518-1220-45EB-9C3E-F4ADA299EE20Q37488273-92F8469A-7610-461E-9425-6C70FDB9CB65Q37598900-80DABABF-E895-49DF-A296-E121E61D014BQ37760931-31B5652B-6F77-4EC0-970E-667B1F5A4E57Q38545655-07F82B72-A5E2-4E5A-AC9F-34F4F8B4D6A9Q38550328-09565392-CF4E-4CD3-9DD6-962FF1B1DB88Q38624994-E5347C09-AFE2-4E08-98EA-82DEAD8F7EE9Q38994958-B209088C-508E-416A-9821-E27F5BC6A901Q39477577-0EE514F6-8701-47F6-825B-B6BA1E4D236BQ40945355-A68B7FAE-966A-417B-B3DB-193309ACBA6AQ42704342-CDB7BCC4-24BF-44C1-B3BF-390823BA29E3Q43644867-9A4D91FF-8E39-4709-8DC1-AB758BE16505Q43861873-3017B1D2-F436-461B-BC8D-C7AE5FFE9F5AQ45161651-A37E01C0-31B1-4D32-B200-3470687E5EADQ45185178-24C65C5F-7979-4735-8E1B-018CDB4F7CD1Q45732990-812474A3-9021-40DC-9A41-F7A816FCB83AQ46915026-B733589B-1940-4806-8EAB-8B15A4718D53Q48057328-B08607F0-2038-4C16-B517-31A47886D07BQ48308232-741FF722-31E3-4BA0-A763-E1A614088583Q48345571-85C0C1A0-FA83-4885-B552-351119C57A14Q51666168-F6E7A2B3-ED85-4BFA-84B6-BD5AB98A09E5Q52017066-FEC1C192-63BB-4841-BFF5-1DBEF120D482Q53716390-AA52A9FD-8A8A-4631-B2A3-29715CECA0A1
P2860
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
@ast
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
@en
type
label
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
@ast
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
@en
prefLabel
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
@ast
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
@en
P1476
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
@en
P2093
P304
P356
10.1016/0920-9964(91)90029-Q
P407
P577
1991-03-01T00:00:00Z